The NYSE-listed, $2-billion drug maker by sales (2020), which is foraying into India's domestic formulations segment with focus on biologics, complex injectables and specialty drugs, will develop novel small molecules and biologic drugs in the country.from Industry-Economic Times
Read The Rest:economictimes...
